Drug Trial Radar · NCT07745361
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Oct 2027
Study completion Apr 2028
Sponsor
- Lead sponsor
- Monte Rosa Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.
Conditions
- Castration-Resistant Prostate Cancer (CRPC)
- Castration-Resistant Prostate Cancer
- Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
Interventions
Oral MRT-2359Drug
Orally administered tablets of MRT-2359
ApalutamideDrug
Orally administered apalutamide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the efficacy of MRT-2359 combined with apalutamideTime frame: 14 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
START Los Angeles
Los Angeles, California · Recruiting
Hoag Memorial Hospital Presbyterian
Newport Beach, California · Not yet recruiting
Rocky Mountain Cancer Center
Colorado Springs, Colorado · Not yet recruiting
Kansas University Cancer Center
Kansas City, Kansas · Not yet recruiting
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland · Not yet recruiting
Henry Ford
Novi, Michigan · Not yet recruiting
XCancer Omaha
Omaha, Nebraska · Recruiting
START New Jersey
East Brunswick, New Jersey · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Not yet recruiting
Lancaster Urology
Lancaster, Pennsylvania · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Not yet recruiting
START Mountain Region
West Valley City, Utah · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
University of Washington Medical Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.